The cash balance suggests the company has sufficient liquidity to fund operations in the near term. Traders should await the full Q2 2026 earnings release (10-Q) for revenue, R&D spend, and cash burn rate to assess the sustainability of the runway.
Price Chart
Executive Summary
Unicycive Therapeutics disclosed a preliminary cash balance of approximately $61.4 million as of June 30, 2026, via an 8-K Item 8.01. The cash position represents roughly 42% of the company's $145M market cap, indicating a strong liquidity buffer for a clinical-stage biotech. No revenue, earnings, or guidance were provided, making this a routine financial update with limited immediate trading implications.
Key Facts
- Ending cash balance of approximately $61.4 million as of June 30, 2026.
- Preliminary, unaudited results for Q2 2026; no full financial statements provided.
- Cash represents ~42% of current market cap ($145M), suggesting ample runway for operations.
Financial Impact
Cash balance of $61.4M disclosed; no revenue, earnings, or burn rate provided.
Risk Factors
- No guidance or operational update provided; cash burn rate unknown.
- Clinical-stage biotech with no approved products; reliance on pipeline milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-074678 |
| Document: 0001213900-26-074678-index-headers.html | 0001213900-26-074678 |
| Document: 0001213900-26-074678-index.html | 0001213900-26-074678 |
| Document: 0001213900-26-074678.txt | 0001213900-26-074678 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 3 | $4.22 | awaiting T+60 | — | $3.51 (−16.94%) |
Sep 29, 2026 28d ago | 8-K | $4.55 | awaiting T+60 | — | $3.51 (−22.97%) |
Aug 12, 2026 10w ago | 8-K | $5.39 | awaiting T+60 | — | $3.51 (−34.97%) |
Jul 2, 2026 16w ago | 8-K | $5.73 $4.81 | ▼ −16.06% | ▼ −19.06% | $3.51 (−38.83%) |
Jun 22, 2026 18w ago | DEFA14A | $7.87 $4.71 | ▼ −40.15% | ▼ −41.90% | $3.51 (−55.46%) |
Jun 16, 2026 19w ago | EFFECT | $7.17 $5.31 | ▲ +25.94% | ▲ +26.94% | $3.51 (+51.12%) |
Jun 5, 2026 20w ago | S-3 | $6.66 $5.05 | ▲ +24.17% | ▲ +27.23% | $3.51 (+47.37%) |
May 12, 2026 24w ago | 8-K | $8.17 $5.05 | ▼ −38.19% | ▼ −42.57% | $3.51 (−57.10%) |
May 12, 2026 24w ago | Press Release | $8.17 $5.05 | ▲ +38.19% | ▲ +42.57% | $3.51 (+57.10%) |
Apr 6, 2026 29w ago | 8-K | $6.62 $5.28 | ▼ −20.24% | ▼ −33.71% | $3.51 (−47.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers